PriceTargets.com logo

InspireMD - NSPR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.75
  • Forecasted Upside: 58.33%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.00 As of 12/20/2024 06:31 PM ET
▲ +0.02 (0.67%)

This chart shows the closing price for NSPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New InspireMD Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NSPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NSPR

Analyst Price Target is $4.75
▲ +58.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for InspireMD in the last 3 months. The average price target is $4.75, with a high forecast of $5.00 and a low forecast of $4.50. The average price target represents a 58.33% upside from the last price of $3.00.

This chart shows the closing price for NSPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in InspireMD.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/11/2024Lake Street CapitalInitiated CoverageBuy$5.00
9/17/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.50
11/2/2023Piper SandlerBoost TargetOverweight ➝ Overweight$3.50 ➝ $4.50
8/9/2023Alliance Global PartnersBoost Target$4.75 ➝ $5.20
6/12/2023Piper SandlerInitiated CoverageOverweight
5/17/2023Alliance Global PartnersLower Target$5.15 ➝ $4.75
(Data available from 12/22/2019 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/23/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024

Current Sentiment

  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
InspireMD logo
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Read More

Today's Range

Now: $3.00
Low: $2.82
High: $3.04

50 Day Range

MA: $2.69
Low: $2.28
High: $3.17

52 Week Range

Now: $3.00
Low: $1.81
High: $3.42

Volume

11,266 shs

Average Volume

29,298 shs

Market Capitalization

$78.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of InspireMD?

The following sell-side analysts have issued stock ratings on InspireMD in the last year: Lake Street Capital, Piper Sandler, and StockNews.com.
View the latest analyst ratings for NSPR.

What is the current price target for InspireMD?

0 Wall Street analysts have set twelve-month price targets for InspireMD in the last year. Their average twelve-month price target is $4.75, suggesting a possible upside of 58.3%. Lake Street Capital has the highest price target set, predicting NSPR will reach $5.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.50 for InspireMD in the next year.
View the latest price targets for NSPR.

What is the current consensus analyst rating for InspireMD?

InspireMD currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NSPR will outperform the market and that investors should add to their positions of InspireMD.
View the latest ratings for NSPR.

What other companies compete with InspireMD?

Other companies that are similar to InspireMD include Sanara MedTech, Zynex, Pulmonx, Electromed and Perspective Therapeutics. Learn More about companies similar to InspireMD.

How do I contact InspireMD's investor relations team?

InspireMD's physical mailing address is 4 MENORAT HAMAOR ST., TEL AVIV L3, 6744832. The company's listed phone number is 9728887766804 and its investor relations email address is [email protected]. The official website for InspireMD is www.inspiremd.com. Learn More about contacing InspireMD investor relations.